Why Axon’s latest results caught investor attention

Axon Enterprise (AXON) drew fresh interest after releasing fourth quarter and full year 2025 results, showing higher revenue alongside much lower net income, and pairing that with new 2026 guidance that calls for 27% to 30% revenue growth.

The earnings release and 2026 guidance arrived alongside a sharp short term move, with a 35.1% 7 day share price return and a 5.5% 1 day gain. The 3 year total shareholder return of about 158% highlights how strong longer term momentum has been.

If Axon’s jump has you thinking about other fast growing tech names tied to AI and automation, it could be worth checking out our screener of 61 profitable AI stocks that aren't just burning cash as a starting list to research.

With Axon up sharply and trading around US$572 after strong multi year returns, the key question now is simple: are you looking at an undervalued growth story, or a stock where the market is already pricing in years of expansion?

Most Popular Narrative: 11.1% Overvalued

According to Vestra’s widely followed narrative, Axon’s fair value sits at $515, which is below the recent $572 share price. This creates a valuation gap investors are debating.

I calculated the $515.00 Fair Value by projecting Axon's Unlevered Free Cash Flow (UFCF), the actual cash the business generates from core operations minus capital expenditures, over the next five years. I then discounted those future cash flows back to today's present value using a Weighted Average Cost of Capital (WACC) of 8.5% to account for market risk, and added a terminal value for its long-term software growth.

For readers interested in the revenue build, margin profile and long-term cash conversion assumptions in that model, and how they relate to Axon’s software-driven mix and public safety focus, the full narrative lays out a detailed playbook behind that $515 fair value estimate.

Result: Fair Value of $515 (OVERVALUED)

However, this story can change quickly if government procurement gets delayed or if Axon’s premium P/E multiple compresses due to even a small wobble in growth expectations.

Next Steps

If this mix of optimism and concern feels familiar, do not wait on others to decide the story for you. Check the 2 key rewards and 3 important warning signs and weigh it against your own view.

Looking for more investment ideas?

Do not stop your research at one company. Broaden your watchlist with a few focused screens that surface different types of opportunities other investors may be overlooking.

• Target potential value plays by scanning our list of 45 high quality undervalued stocks that pair pricing with underlying business quality.
• Prioritise resilience by reviewing a solid balance sheet and fundamentals stocks screener (41 results) that can help you focus on companies with stronger financial footing.
• Boost your income shortlist by assessing a curated set of 13 dividend fortresses that offer higher yields to research further.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.